MUSCAT: The achievement strengthens Oman’s engagement with international regulatory bodies and provides an opportunity to benefit from global expertise in pharmaceutical quality, safety and efficacy.
The ICH is an international platform that brings together pharmaceutical regulatory authorities and industry representatives to harmonise technical requirements and develop scientific guidelines and standards for medicines.
The observer status will allow Oman to follow international regulatory and scientific developments, exchange expertise, strengthen national capabilities and work towards aligning its pharmaceutical regulatory requirements with internationally recognised guidelines.
During the next phase, the Drug Safety Center plans to train specialists in regulatory assessment, gradually implement ICH guidelines and support the development of local pharmaceutical manufacturing through enhanced technical capabilities at national factories.
The centre also aims to strengthen cooperation and exchange expertise with ICH member countries and participating organisations.
The development forms part of the Ministry of Health’s efforts to advance Oman’s pharmaceutical sector and strengthen its regulatory framework, in line with the objectives of Oman Vision 2040 to build an efficient and sustainable healthcare system.
Read More
- Oman confirms Nov. 25–26 National Day holiday
- Oman launches air bridge to deliver humanitarian aid to Nepal
- His Majesty Sultan Haitham begins inspection tour of wilayats in Al Dakhiliyah Governorate
- Oman’s tradition of listening can guide economic decisions, TAS CEO tells Conclave
- 12 expats arrested in Oman for labour and residency violations





